Healthcare giant Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Caplyta ...

Danish diabetes and obesity drug giant Novo Nordisk has agreed with the US Administration to lower drug prices beginning in ...

Danish pharma major Novo Nordisk (NOV: N) has presented new post-hoc analyses from the Phase III REDEFINE 1 trial evaluating ...

The global endometrial cancer market is on course for steady expansion, projected to reach nearly $39 billion by 2030. Growth ...

German pharma major Bayer announced new Phase III investigational data from the pivotal FINE-ONE trial showing that Kerendia ...

Eli Lilly (NYSE: LLY) is preparing to start Phase III trials of its experimental obesity therapy eloralintide by year-end, ...

Belgian biopharma company UCB (Euronext: UCB) has announced a leadership reshuffle, effective January 1, 2026, as part of a ...

The USA’s Centers for Medicare & Medicaid Services (CMS) is tackling high drug prices and protecting the American taxpayers ...

The Russian government has proposed a new mechanism for subsidization of works for development of new drugs, reports The ...

US pharma major Eli Lilly has announced an agreement with the US government to expand access to its obesity medicines and reduce patient costs.

The Russian government has approved the allocation of 140 billion roubles ($1.72 billion) annually for the treatment of ...

US biopharma company Ultragenyx Pharmaceutical today announced the sale, for $400 million, of an additional 25% of the ...